Australia's first large-scale mRNA vaccine manufacturing facility

Designed by architects Greenbox, CRB and IPS, the 16,500 square metre facility comprises pharmaceutical grade space including Drug Substance (DS) and Drug Product (DP) areas. It also includes laboratories, administration areas with office space and employee amenities, as well as a warehouse with loading dock.

The facility will be able to produce COVID-19 vaccines as well as mRNA vaccines for other respiratory viruses. It will also provide Australia with an onshore mRNA manufacturing capability in the event of a new pandemic.